General Motors has a new model that’s sparking a lot of interest around the world. The automaker’s China joint venture […] ...

The upcoming, all-new Chevy Spark EUV will join the brand’s lineup in Brazil this year as its most affordable fully electric ...

To help you find the very best electric car for your money, our expert road testers have thoroughly tested every new EV that you can buy in the UK. Our in-depth reviews examine the full package ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Novo Nordisk A/S’s failure to meet its own bar for success on a next-generation obesity shot shows the danger of promising too much in the cut-throat market for weight-loss drugs. The Danish ...

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...

Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off of the stock. "We are ...

The long-standing edge that Novo Nordisk has held in the obesity drug market was thrown into question Friday when the company reported results of a closely watched candidate that fell short of ...

LONDON/COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug ...

Novo Nordisk’s focus on obesity treatments has grown stronger with its CagriSema drug, which combines cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist). This ...

Gift 5 articles to anyone you choose each month when you subscribe. Huawei was not around for that first automotive revolution, but despite being heavily targeted by US sanctions, the Chinese tech ...